These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 6285809)
21. [Clinical and pharmacokinetic study on cefodizime, a new cephalosporin antibiotic, in the pediatric infections]. Arimasu O; Meguro H; Hiruma F; Sugie N; Abe T Jpn J Antibiot; 1989 Jun; 42(6):1293-305. PubMed ID: 2795854 [TBL] [Abstract][Full Text] [Related]
22. Ceftriaxone administered once or twice a day for treatment of bacterial infections of childhood. Higham M; Cunningham FM; Teele DW Pediatr Infect Dis; 1985; 4(1):22-6. PubMed ID: 3969362 [TBL] [Abstract][Full Text] [Related]
23. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Francke EL; Neu HC Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426 [TBL] [Abstract][Full Text] [Related]
29. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638 [TBL] [Abstract][Full Text] [Related]
30. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. Holloway WJ; Palmer D Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098 [TBL] [Abstract][Full Text] [Related]
31. Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries. Garzone P; Lyon J; Yu VL Drug Intell Clin Pharm; 1983 Sep; 17(9):615-22. PubMed ID: 6311502 [TBL] [Abstract][Full Text] [Related]
32. In vitro activity of cefodizime (HR-221). Ahonkhai VI; Cherubin CE; Shulman MA Antimicrob Agents Chemother; 1982 Oct; 22(4):715-8. PubMed ID: 6295264 [TBL] [Abstract][Full Text] [Related]
33. [Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli]. Naessens A; Pierard D; Roels P; Lauwers S Pathol Biol (Paris); 1983 May; 31(5):362-5. PubMed ID: 6312398 [TBL] [Abstract][Full Text] [Related]
34. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Neu HC; Meropol NJ; Fu KP Antimicrob Agents Chemother; 1981 Mar; 19(3):414-23. PubMed ID: 6972729 [TBL] [Abstract][Full Text] [Related]
35. Clinical trials of cefotaxime for the treatment of bacterial infections of the lower respiratory tract. Perkins RL Rev Infect Dis; 1982; 4 Suppl():S421-31. PubMed ID: 6294794 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation and perspectives of a new cephalosporin: ceftriaxone]. Auvergnat JC; Armengaud M Rev Med Interne; 1985 Mar; 6(2):187-92. PubMed ID: 3839091 [TBL] [Abstract][Full Text] [Related]
37. Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use. Neu HC Pharmacotherapy; 1984; 4(2):47-60. PubMed ID: 6326062 [TBL] [Abstract][Full Text] [Related]
38. Ceftriaxone: pharmacokinetics and effect on the intestinal microflora in patients with acute bacterial infections. Nilsson-Ehle I; Nord CE; Ursing B Scand J Infect Dis; 1985; 17(1):77-82. PubMed ID: 3992209 [TBL] [Abstract][Full Text] [Related]
40. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime. Norrby SR Am J Med; 1985 Aug; 79(2A):56-61. PubMed ID: 3895919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]